Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 1.1% – Should You Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s stock price was up 1.1% during mid-day trading on Friday . The stock traded as high as $10.40 and last traded at $9.78. Approximately 220,419 shares were traded during mid-day trading, a decline of 84% from the average daily volume of 1,377,421 shares. The stock had previously closed at $9.67.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on shares of Tonix Pharmaceuticals in a report on Monday, February 10th. They issued a “sell” rating on the stock.

Tonix Pharmaceuticals Stock Performance

The firm’s 50-day simple moving average is $28.22 and its two-hundred day simple moving average is $23.68. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The company has a market cap of $18.23 million, a PE ratio of 0.00 and a beta of 2.07.

Hedge Funds Weigh In On Tonix Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Commonwealth Equity Services LLC acquired a new position in shares of Tonix Pharmaceuticals during the fourth quarter worth about $40,000. Two Sigma Investments LP purchased a new stake in shares of Tonix Pharmaceuticals in the 4th quarter valued at approximately $66,000. PFG Investments LLC purchased a new stake in shares of Tonix Pharmaceuticals during the 4th quarter worth $72,000. Northern Trust Corp purchased a new position in Tonix Pharmaceuticals in the fourth quarter valued at $162,000. Finally, Point72 Asset Management L.P. purchased a new position in shares of Tonix Pharmaceuticals in the 4th quarter valued at about $526,000. Hedge funds and other institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.